Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas

US7371763B2 · kind B2 · utility

Assignee

• Bayer Pharmaceuticals Corporation · US

Inventors

• Jacques Dumas · Neuilly-Plaisance, FR
• Bernd Riedl · Wuppertal, DE
• Uday Khire · Hamden, US
• Robert Sibley · North Haven, US
• Holia Hatoum-Mokdad · Hamden, US
• Mary-Katherine Monahan · Hamden, US
• David Gunn · Waukegan, US
• Timotthy B. Lowinger · Nishinomiya, JP
• William Scott · Guilford, US
• Roger Smith · Madison, US
• Jill Wood · Hampton, US

Key dates

• Filing date: Jun 22, 2005
• Grant date: May 13, 2008
• Expiry date: Jun 24, 2025

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/00
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The invention relates to a group of quinolyl, isoquinolyl and pyridyl ureas, their the use in treating raf mediated diseases, and pharmaceutical compositions which contain these ureas for use in such therapy.